livemint.com
52%
594
Zydus Cadila gets DGCI nod to start phase 3 trials of Covid-19 vaccine on patients
Also read | Inside the race to save MollemThe drug firm had completed the phase 2 clinical trials with PegiHep last month.Zydus Cadila, in a regulatory filing on Friday, has said that it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.Trials to be conducted on 250 patientsThe trials, which will commence in December, will be conducted on 250 patients across 20-25 centres in the country, according to the company filing.Speaking on the matter, Sharvil Patel, Managing Director of Cadila Healthcare Ltd, said, "We are encouraged by the results of phase 2 study of Pegylated Interferon alpha 2-b which has shown the potential to reduce